""""""""The Retroviral Diseases Section of the HIV and AIDS Malignancy Branch conducts translational clinical and laboratory research aimed at the development of novel therapies for HIV infection and AIDS- related malignancies. It also conducts laboratory research focused on an understanding of these diseases. During the past year, the group has investigated the role of conserved cysteines at positions 67 and 95 on the activity of HIV protease. We have found that glutathiolation of Cys 95 abolishes HIV-1 protease activity, while glutathiolation of Cys 67 can enhance activity. HIV virions with mutations of Cys 95 and Cys67 have been generated and we are studying the effects that these mutations have on the fitness of HIV under varying conditions. We are exploring the regulation of HIV-2 protease and have preliminary results showing that a methionine in position 95 of HIV-2 acts in a way similar to the cysteine in position 95 of HIV-1 in terms of regulating the protease activity. We are in the process of extending these observations to the proteases of other retroviruses. Other laboratory studies have involved a study of the differential ability of protease inhibitors in monocytes and lymphocytes and the mechanisms that might cause these differences. We have also continued the investigation of the combined activity of a newly discovered herpesvirus, called Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8), and HIV in the pathogenesis of Kaposi's sarcoma (KS). We are also conducting several clinical trials to evaluate novel therapies for Kaposi's sarcoma. We have recently obtained preliminary results indicating that the anti-angiogenesis agent thalidomide is active in a subset of patients with Kaposi's sarcoma. We are also studying IL-12 for possible activity in Kaposi's sarcoma and also the anti- herpes drug cidofovir and its effect on the expression of KSHV-related genes in KS. We are also studying infusional chemotherapy and IL-12 as therapy for AIDS-associated lymphoma. In regard to anti-HIV therapy, we have initiated clinical trials of the dideoxynucleoside reverse transcriptase inhibitor beta-fluoro-dideoxyadenosine (FddA) in adults, both alone and in a combination regimen. This drug is active in vitro even against strains of HIV that are resistant to a number of other dideoxynucleosides. We are planning a study of this agent used in combination with hydroxyurea, which potentiates the activity of F-ddA in vitro by increasing the intracellular ratio of F-ddA-triphosphate to ddATP. In addition, a clinical trial is under way to study two HIV envelope peptide vaccines in HIV-infected patients in combination with highly active antiretroviral therapy. Preliminary results indicate that the vaccine can boost proliferative T cell responses against HIV in a majority of patients. The project is 100% AIDS research (about 50% is both AIDS and cancer).""""""""
Showing the most recent 10 out of 40 publications
